DEEP DIVE
🗣️ ASDS 2026: what practices were saying
We spent our time at ASDS 2026 in San Diego talking with dermatologists across the spectrum: residents, academic physicians, practice owners, and employed physicians. The conversations covered a lot of ground, but three things came up again and again. This is what we heard over a few days at one meeting, not survey data, so read it as a snapshot of what's on people's minds.
The 2027 cuts and why they land hard
The worry we heard most was about Medicare's 2027 cuts. People were frustrated to see Medicare change how it pays for office overhead just as overhead keeps getting more expensive.
The change is real. Under the CY 2027 Physician Fee Schedule final rule, which takes effect Jan 1, 2027, Medicare is removing the Indirect Practice Cost Index (IPCI). That's an old formula, built on survey data from 2007 and 2008, that gave some specialties extra credit for office overhead. The removal phases in over 2 years, half in 2027 and the rest in 2028.
Separately, a 5% stabilization adjustment caps how much most existing codes' practice-expense values can change in one year. CMS calls these distinct mechanisms that work together. It names dermatology among the specialties with a significant estimated decrease, mostly because of the same-day policy and the IPCI removal, with the cap softening part of the hit.
That lands at a hard time. As MGMA noted last week, consumer prices rose 3.7% in the 12 months ending in September. The conversion factor, the dollar multiplier behind every payment, also drops about 2% as Congress's one-year 2.5% bump for 2026 expires. It falls to $32.6286 for most clinicians and $32.9548 for qualifying participants in advanced alternative payment models. These are separate changes, so don't add them into one number for your practice.
Why does derm feel this more than most? The explanation we kept hearing was the shape of the field. Dermatology is medical, surgical, and cosmetic at once, with a lot of procedures and a lot of office overhead, so changes aimed at procedures and practice expense reach it from several directions.
The same-day cut is part of that. We covered the rule in our Nov 9 issue: starting Jan 1, when a separately identifiable office E/M visit with modifier 25 happens on the same day as a 0-day global procedure, the lower-paid service is paid at 80%. A coalition of 62 physician groups, including the American Academy of Dermatology Association and the American College of Mohs Surgery, wrote to congressional leaders on Nov 12 asking them to delay the cut by one year. Unless Congress acts, the 2027 rule stands as final, so plan with it as written.
People also kept coming back to efficiency. With less coming in per service, delivering care efficiently matters more than ever, from how clinicians spend their time to how each visit runs.
Advocacy came up too. SkinPAC is the AADA's federal political action committee, funded by AADA members. With so much of what derm practices get paid now decided in rulemaking and in Congress, we think lobbying, and making sure our specialty has a seat at the table, has never been more important.
AI came up in almost every conversation
AI came up in almost every conversation at ASDS earlier this month, and it got its own stage too. Our friends Drs. Matthew Elias, Kim Edhegard, Farhaad Riyaz, and Cory Maughan led a panel about AI in dermatology. It was one of the most interactive sessions of the meeting, with a room full of dermatologists trading their own experiences. The panel stuck to real-world uses that are already changing how practices run. Dr. Elias's takeaway was that AI in derm has stopped being a future question. Practices are using it now.
A scoping review from Mayo Clinic's Dr. Rewan Abdelwahab, presented at ASDS, was more cautious. It found AI promising, especially for coding and billing with staff checking the output, but not ready to work on its own. It also said a physician should review any AI-written patient education materials before they go out.
What we liked in the exhibit hall
This is the stuff we thought was cool. Fair warning: we're a bunch of billers, so none of it's an endorsement, and we can't speak to whether anything works clinically. Product claims are the companies' own.
Tiger Aesthetics. Its donor-fat injectable, alloClae, is on sale now for body contouring. Its face and hand version, dermaClae, was only previewed, and Tiger says it launches in early 2027. Tiger classifies alloClae as a 361 HCT/P tissue product, a category that doesn't go through FDA clearance or approval, so alloClae isn't an FDA-cleared filler.
Re-Q. One of two Carlsbad brands in the mix, with "pro-longevity" serums.
Ourself. The other Carlsbad brand, and points for the name: its "Lip Filler" is a topical, not an injectable.
Oathology. We're always proud to see our clients as entrepreneurs. Board-certified dermatologists Dr. Divya Shokeen and Dr. Mona Mislankar built Oathology for the patient who walks in with a bag of ten products and no idea what's working. The idea is 'curated over cluttered': a short list of multi-benefit products, including a vitamin C serum, a retinoid serum, and SPF 50+ sunscreens, so patients get a routine they'll stick with. Oathology says it will always cost patients less in your office than online. Try it with code TBCD40, or email [email protected] about wholesale pricing.
BV Laser. This was the busiest laser booth we saw, with about three times the crowd the other laser makers drew. The reason: laser hair removal, fractional, and CO2 lasers at a fraction of the usual cost. Is it too good to be true? Maybe, but a bunch of us decided to take the plunge.
Takeaways
Plan for 2027 with the rule as written. Budget with the published conversion factor, and remember the overhead change phases in over two years, with a separate yearly cap per code. Don't fold it all into one combined cut. Revisit only if Congress actually acts.
Make efficiency a 2027 priority. With less coming in per service, look for places where clinicians spend time on work others could handle, and decide same-day procedures case by case based on clinical need rather than a blanket rule.
Slow down when a price looks too good. Verify the exact unit's clearance, and get service and training terms in writing.
What did you hear at ASDS, or what are you seeing in your own practice as 2027 gets closer? Hit reply and tell us.
UPCOMING EVENTS + REMINDERS
📆 Mark your calendars:
Medicare participation enrollment for 2027: mid-November through December 31. During the annual enrollment window, you can stay participating by doing nothing, leave by sending written notice to each Part B MAC postmarked before December 31, or join by mailing CMS-460. Non-participating providers are paid 5% less than the fee-schedule amount and are subject to the limiting charge, so decide your 2027 status with the new rates in hand.
MIPS exception applications for the 2026 performance year: December 31, 2026, 8 p.m. ET. If EHR trouble, a cyber incident, or a similar event disrupted 2026 reporting, submit a Promoting Interoperability Hardship or Extreme and Uncontrollable Circumstances application before the deadline. Small practices are already automatically excepted from Promoting Interoperability.


Built by the people who do this every day.
Clarity RCM manages revenue cycle for 200+ dermatology practices across 44 states. It's all we do. See how we work.

